Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia

Evelien Krumb MD | Cedric Hermans MD, FCRP, (Lon, Edin), PhD

Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium

Correspondence
Cedric Hermans, Head Division of Hematology, Hemostasis and Thrombosis Unit, Hemophilia Clinic, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 10, B-1200 Brussels, Belgium.
Email: cedric.hermans@uclouvain.be

Handling Editor: Dr Susan Kahn.

Abstract
Direct oral anticoagulants (DOACs) are widely used in several indications, but data on their efficacy and safety in individuals affected by severe inherited thrombophilia, yet without any personal history of thrombosis, is lacking. Severe inherited thrombophilia abnormalities, especially antithrombin deficiency, confer a higher risk of developing venous thromboembolism (VTE) than is the case in the general population. In this article, we propose primary prevention with low-dose DOACs for certain patients with severe inherited thrombophilia but without any personal history of VTE, while taking into consideration the type of thrombophilia, family history, comorbidities, and bleeding risk.

KEYWORDS
anticoagulants, antithrombin deficiency, apixaban, rivaroxaban, thrombophilia, venous thromboembolism

Essentials
• Direct oral anticoagulants (DOACs) are effective and safe in several indications.
• Recent data seem to support treatment of venous thromboembolism with DOACs in severe inherited thrombophilia.
• We suggest considering primary prophylaxis with low-dose DOACs in high-risk thrombophilia.
• Further research on safety and efficacy of DOACs in this indication is needed.
pulmonary embolism, with smoking and oral contraception identified as the sole risk factors at that time; one DVT in 1996 following a long-haul flight; and one DVT during pregnancy in 2002. The patient was diagnosed with antithrombin (AT) deficiency in 1997. Her AT level was estimated at 43% (normal range, 78%-130%), using a functional chromogenic assay. Genetic testing conducted later confirmed a type I deficiency (nonsense mutation c.1171C > T, p.Arg 391* in exon 5).

Our patient’s daughter was born in 2003. Shortly after her birth, she underwent aortic coarctation surgery, which was complicated by cardiogenic shock and thrombus formation in the descending aorta and left subclavian artery. Considering her personal and family thrombosis history and in agreement with international guidelines, she was referred to us for genetic screening in 2006, which revealed the same mutation in the AT gene as in her mother. Her AT level was measured at 42%, based on a functional chromogenic assay. To date, this patient has not presented with any further venous or arterial thrombotic events, in spite of not being administered any anticoagulant therapy. However, she has been advised to avoid contraceptives containing estrogen and was informed about the necessity of thromboprophylaxis in high-risk situations, such as surgery, pregnancy, or long-distance flights, as recommended in the literature.1

Overall, individuals with AT deficiency display a greater risk of developing VTE than the general population, their relative risk of developing a first VTE being the highest among all inherited thrombophilia,2 and especially high compared to other conditions predisposing to arterial or venous thrombosis (Table 1). Notably, the risk of thrombosis associated with AT deficiency depends on the defect type, with patients affected by a homozygous AT type II heparin-binding site defect bearing the highest risk.1 Given their high VTE risk, we now consider conducting primary prophylaxis with a low-dose DOAC (eg, rivaroxaban 10 mg once daily or apixaban 2.5 mg twice daily) for individuals exhibiting AT deficiency with a positive VTE family history, yet without any personal VTE events in the past. This preventive approach is, nonetheless, not supported by published evidence. The latest American College of Chest Physicians guidelines do not provide any recommendations concerning the antithrombotic management of these patients. When we consider the increasing number of individuals that are diagnosed with severe thrombophilia following systematic family screening and risk-benefit ratio of DOACs given at a low dose in secondary VTE prevention, it must be emphasized that there is clearly an unmet need for further research on extended primary thromboprophylaxis with low-dose DOACs in this setting.

Given that DOACs are already safely and efficiently used in several indications of primary and secondary venous or arterial thrombosis prevention, we suggest that it may be justified to consider and evaluate their long-term prophylactic use at low doses in patients with severe inherited thrombophilia that are at a high risk of thrombosis. Indeed, DOACs constitute the treatment of choice for stroke prevention in patients with nonvalvular atrial fibrillation, for which they have been proven to be as effective as and even safer than VKA.3 Notably, most AF patients undergoing DOAC therapy have, in fact, never experienced any arterial thrombotic events; thus, they are given this therapy for primary prevention.

Low-dose aspirin has been approved for primary arterial thrombosis prevention in carefully selected patients and for secondary prevention in most patients with past arterial thrombotic events. Interestingly, in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, very-low-dose DOAC (rivaroxaban 2.5 mg twice daily) associated with low-dose aspirin was found to significantly reduce the risk of major cardiovascular adverse events and limb ischemia in patients suffering from peripheral artery disease.4 The risk of major bleeding was found to be enhanced with this dual therapy, whereas no significant increase in fatal or critical organ bleeding was noted.

Notably, following major orthopedic surgery like total hip or knee replacement, DOACs are increasingly prescribed at low doses for the primary prevention of surgery-related thrombosis.5 In the latest American Society of Clinical Oncology guidelines on thromboprophylaxis in patients with cancer, primary prevention of VTE with apixaban, rivaroxaban, or low-molecular-weight heparin is now recommended for high-risk ambulatory patients with cancer.6 In light of recent findings, an increasing number of patients with a past VTE history may now benefit from long-term secondary prevention with low-dose DOACs, particularly rivaroxaban and apixaban. When used at low doses, these latter drugs have demonstrated antithrombotic efficacy, along with a low major bleeding risk.7 In the AMPLIFY-EXT (Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism) trial, major bleeding occurred in 0.2% of patients receiving apixaban at 2.5 mg twice daily for extended secondary VTE prevention (12 months after 6-12 months of VTE treatment) versus 0.5% of patients in the placebo group. In the Einstein Choice (Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic

| Risk factor                                | Risk of ischemic stroke or venous thromboembolic event |
|--------------------------------------------|--------------------------------------------------------|
| Atrial fibrillation                        | Ischemic stroke: RR, 2.33 (95% CI, 1.84-2.94)          | 12 |
| Previous VTE                               | Recurrence: OR, 15.6 (95% CI, 6.77-35.89)              | 13 |
| Heterozygous factor V Leiden               | First VTE: OR, 4.22 (95% CI, 3.35-5.32)                | 14 |
| Antithrombin deficiency (types I + II)      | First VTE: OR, 14.0 (95% CI, 5.5-29.0)                 | 15 |
|                                           | Annual absolute risk of VTE, 1.2% (95% CI, 0.8%-1.7%)  | 15 |

Table 1 Risk of arterial or venous thrombosis according to the underlying condition

Abbreviations: CI, confidence interval; OR, odds ratio; RR, relative risk; VTE, venous thromboembolism.
Venous Thromboembolism) study, 0.4% of patients receiving rivaroxaban at 10 mg once daily for 12 months suffered from major bleeding versus 0.3% in the aspirin group. It should be noted that the risk of major bleeding and clinically relevant nonmajor bleeding rises when DOACs are given at a full dose for extended secondary prevention.

Finally, data on DOAC use following VTE in patients with severe inherited thrombophilia have meanwhile been reported. In a meta-analysis and systematic review by Elsebaie et al., DOACs were found to be as effective as VKA in patients with thrombophilia (VTE recurrence risk: relative risk [RR], 0.84 [95% confidence interval (CI), 0.32-2.19]; risk of clinically relevant bleeding: RR, 0.92 [95% CI, 0.62-1.36]). However, this meta-analysis exhibited several limitations, including a low number of thrombotic events in the analyzed subgroups, as well as potential selection bias for low-risk patients in the APS subgroup, therefore rendering it impossible to precisely determine DOACs’ efficacy and safety in either triple-positive APS or APS with a history of arterial thrombi.

Recently, data from the first-ever prospective cohort study focused on DOACs versus heparin and VKA for VTE treatment and secondary prevention in patients with inherited thrombophilia was published by Campello et al. In this study including a large cohort of patients with thrombophilia experiencing VTE (n = 597), the DOAC efficacy in preventing VTE recurrence was comparable to that observed with VKA and heparin (cumulative incidence of recurrence during anticoagulation, 1.09% [95% CI, 0.22%-3.31%] in DOAC-treated patients versus 1.83% [95% CI, 0.74%-4.3%] in controls). For all recurrent events in the DOAC group (n = 3), precipitating factors could be demonstrated, including insufficient compliance, polycythemia vera, and APS occurrence. Notably, DOACs were revealed to be effective in a subgroup of patients with severe thrombophilia (cumulative incidence of recurrence, 2.2% [95% CI, 0.13%-8.14%] in DOAC-treated patients versus 1.77% [95% CI, 0.09%-6.62%] in controls).

Interestingly, the incidence of recurrent VTE events following anticoagulation discontinuation was significantly lower in the DOAC group versus the VKA/heparin group (9.8% [95% CI, 5.73%-16.24%] versus 21.2% [95% CI, 16.26%-27.14%] in controls). The bleeding risk was significantly higher in DOAC group (cumulative incidence, 10.2% [95% CI, 7.09%-14.36%] versus 4.97% [95% CI, 3.02%-7.97%] in controls). Nonetheless, major bleeding (n = 3) occurred only in the control group. DOACs were associated with a higher risk of clinically relevant nonmajor bleeding, especially menometrorrhagia. These study’s limitations included the small sample size of patients with severe thrombophilia, in spite of all severe inherited thrombophilia types being included in the analysis. These findings, which are highly relevant for clinicians, appear to confirm DOACs’ efficacy and safety in patients afflicted with inherited thrombophilia.

In conclusion, primary VTE prophylaxis using a DOAC should be considered in patients with AT deficiency or other severe inherited thrombophilia forms who carry a high risk of thrombosis. Family history, underlying genetic variants, presence of comorbidities, and risk factors for bleeding should be carefully taken into account. Recent data of a prospective cohort study are suggestive of DOACs’ antithrombotic efficacy and safety in patients with severe thrombophilia and VTE. Further studies, whether randomized prospective trials or retrospective studies, are urgently needed to confirm these encouraging results in patients with AT deficiency and other severe inherited thrombophilia disorders.

**RELATIONSHIP DISCLOSURE**

The authors declare no conflict of interest.

**AUTHOR CONTRIBUTIONS**

All authors wrote and approved the final version of the manuscript.

**ORCID**

Evelen Krumb @https://orcid.org/0000-0001-8270-8819
Cedric Hermans @https://orcid.org/0000-0001-5429-8437

**REFERENCES**

1. Pabinger I, Thaler J. How I treat patients with hereditary antithrombin deficiency. Blood. 2019;134(26):2346–53.
2. Phillippe HM, Hornsby LB, Treadway S, Armstrong EM, Bellone JM. Inherited thrombophilia. J Pharm Pract. 2014;27(3):227–33.
3. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–44.
4. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–29.
5. Papadopoulos DV, Kostas-Agnantis I, Gkiatas I, Tsantes AG, Ziara P, Korompilias AV. The role of new oral anticoagulants in orthopaedics: an update of recent evidence. Eur J Orthop Surg Traumatol. 2017;27(5):573–82.
6. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520.
7. Imberti D, Pomer F, Mastroiacovo D. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. Blood Transfus. 2020;18(1):49–57.
8. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.
9. Weitz JI, Lensing AWA, Prins MH, Bausersh R, Beyer-Westendorf J, Bounamaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211–22.
10. Sardar P, Chatterjee S, Mukherjee D. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials. *Drugs*. 2013;73(11):1171–82.

11. Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. *J Thromb Haemost*. 2019;17:645–56.

12. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ*. 2016;i4482.

13. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. *Arch Intern Med*. 2000;160(22):3415–20.

14. Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. *Eur J Epidemiol*. 2013;28(8):621–47.

15. Croles FN, Borjas-Howard J, Nasserinejad K, Leebeek FWG, Meijer K. Risk of venous thrombosis in antithrombin deficiency: a systematic review and bayesian meta-analysis. *Semin Thromb Hemost*. 2018;44(4):315–26.

16. Campello E, Spiezia L, Simion C, Tormene D, Camporese G, Dalla Valle F, et al. Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. *J Am Heart Assoc*. 2020;9(23):e018917.

How to cite this article: Krumb E, Hermans C. Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia. *Res Pract Thromb Haemost*. 2021;5:261–264. [https://doi.org/10.1002/rth2.12479](https://doi.org/10.1002/rth2.12479)